What If NeuVax is Given "Breakthough Designation" by the FDA!!!
This is a possibilty GALE investors cannot overlook.
On March 15th, Novartis (NVS), Europe's largest pharma company received such status from the FDA for its LDK378 compound that treats lung cancer, just after the Phase1 trial with just 88 patients. Nearly 4/5 of the volunteers participated in the trial shrank their tumors.
NVS is seekking approval for the drug within a year while conducting P2/3 trials.
If such a thing happens, GALE will be off to the moon with just $200mm MC!
some of the FDA approvals granted Herceptin were based on data less compelling than some of the data derived during Phase II of NeuVax testing. ALSO, whereas Herceptin is infused with great regard for its potential damage to certain tissue (heart for example), NeuVax is COMPLETELY SAFE - equivalent to receiving the tetanus or polio or flu vaccine. Conclusion: if it does not harm AND if it is able to demonstrate statistically significant GOOD, then LET IT RIDE!